Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)
Clinical trial NCT04745130 · UNKNOWN
Trial details
- NCT number
- NCT04745130
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2023-02-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.